FMP
Regencell Bioscience Holdings Limited
RGC
NASDAQ
Regencell Bioscience Holdings Limited operates a Traditional Chinese medicine (TCM) bioscience company. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily attention deficit hyperactivity disorder and autism spectrum disorder. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong.
12.62 USD
-1.47 (-11.65%)
RGC Financial Statements
Quarter
2024 Q4
2024 Q2
2024 Q1
2023 Q4
Total Revenue
0
0
0
0
Cost of Revenue
0
0
0
769.69k
Gross Profit
0
0
0
-769.69k
Operating Expenses
2.42M
1.16k
1.16k
2.07M
Research and Development
581.48k
242.38
242.38
231.46k
Selling, General & Administrative Expenses
1.84M
913.55
913.55
1.84M
Selling & Marketing Expenses
0
48.53
48.53
82.28
General & Administrative Expenses
0
865.02
865.02
1.04k
Other Expenses
0
0
0
0
Operating Income
-2.42M
-1.16k
-1.16k
-2.84M
Total Other Income/Expenses Net
247.54k
-1.03M
-1.09M
97.06k
Income Before Tax
-2.18M
-1.09k
-1.09k
-2.75M
Income Tax
57.89k
-119.27k
-59.64
-103.33k
Net Income
-2.24M
-1.03k
-1.03k
-2.64M
Basic EPS
-0.17
-0
-0.08
-0.2
EPS Diluted
-0.17
-0
-0.08
-0.2
Basic Average Shares
13.01M
13.01M
13.01M
13.01M
Diluted Average Shares
13.01M
13.01M
13.01M
13.01M
EBITDA
-2.18M
-2.19M
-1.08M
-1.98M
Retained Earning Schedule
Quarter
2024 Q4
2024 Q2
2024 Q1
2023 Q4
Retained Earnings (Previous Year)
0
0
-17.32M
-17.32M
Net Income
-2.24M
-1.03k
-1.03k
-2.64M
Stock Repurchases
0
0
0
0
Dividend Paid
0
0
0
0
Retained Earnings
-21.62M
0
0
-17.32M
Other Distributions
-21.62M
0
17.32M
0
PPE Schedule
Quarter
2024 Q4
2024 Q2
2024 Q1
2023 Q4
Gross PPE
226.51k
0
0
891.91k
Annual Depreciation
247.54k
73.28
73.28
769.69k
Capital Expenditure
0
0
0
0
Net PPE
-21.03k
-73.28
-73.28
122.23k
Intangible and Goodwill Schedule
Quarter
2024 Q4
2024 Q2
2024 Q1
2023 Q4
Acquisitions and Adjustments
0
0
0
0
Goodwill (Previous Year)
0
0
0
0
Goodwill
0
0
0
0
All figures are in USD.
